Movement Alert｜WUXI BIO Falls 3.15% in Regular Trading, Life Sciences Sector Broadly Weakens as Subsidiary Faces Target Price Cut

Market Focus

Jul 30

On July 30, WUXI BIO fell 3.15% in regular trading, trading at HK$38.18/share, with turnover of HK$278 million. The decline came amid broad-based weakness across the Life Sciences Tools and Services sector.

On the news front, the selloff appears linked to sector-wide profit-taking following a strong recent rally, compounded by Nomura's downgrade of WUXI BIO's subsidiary WUXI XDC's target price from HK$87.73 to HK$82.6 on July 29. Nomura cited higher FX losses and elevated management expenses related to the Dong Yao Pharma acquisition, cutting its fiscal year earnings forecast by 22.3%. WUXI XDC itself declined over 4% on the day.

Within the sector, INSILICO fell 2.57%, WUXI APPTEC fell 2.02%, XTALPI fell 1.47%, GENSCRIPT BIO fell 0.92%, and WUXI XDC fell 4.15%. The company is scheduled to report interim results on August 25.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1184004568"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1184004568\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1184004568?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-30 10:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1184004568","market":"hk","top_or_hot":-1,"title":"Movement Alert｜WUXI BIO Falls 3.15% in Regular Trading, Life Sciences Sector Broadly Weakens as Subsidiary Faces Target Price Cut","media":"Market Focus","content":"<p><p>On July 30, WUXI BIO fell 3.15% in regular trading, trading at HK$38.18/share, with turnover of HK$278 million. The decline came amid broad-based weakness across the Life Sciences Tools and Services sector.</p><p>On the news front, the selloff appears linked to sector-wide profit-taking following a strong recent rally, compounded by Nomura's downgrade of WUXI BIO's subsidiary WUXI XDC's target price from HK$87.73 to HK$82.6 on July 29. Nomura cited higher FX losses and elevated management expenses related to the Dong Yao Pharma acquisition, cutting its fiscal year earnings forecast by 22.3%. WUXI XDC itself declined over 4% on the day.</p><p>Within the sector, INSILICO fell 2.57%, WUXI APPTEC fell 2.02%, XTALPI fell 1.47%, GENSCRIPT BIO fell 0.92%, and WUXI XDC fell 4.15%. The company is scheduled to report interim results on August 25.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜WUXI BIO Falls 3.15% in Regular Trading, Life Sciences Sector Broadly Weakens as Subsidiary Faces Target Price Cut</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜WUXI BIO Falls 3.15% in Regular Trading, Life Sciences Sector Broadly Weakens as Subsidiary Faces Target Price Cut\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-30 10:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 30, WUXI BIO fell 3.15% in regular trading, trading at HK$38.18/share, with turnover of HK$278 million. The decline came amid broad-based weakness across the Life Sciences Tools and Services sector.</p><p>On the news front, the selloff appears linked to sector-wide profit-taking following a strong recent rally, compounded by Nomura's downgrade of WUXI BIO's subsidiary WUXI XDC's target price from HK$87.73 to HK$82.6 on July 29. Nomura cited higher FX losses and elevated management expenses related to the Dong Yao Pharma acquisition, cutting its fiscal year earnings forecast by 22.3%. WUXI XDC itself declined over 4% on the day.</p><p>Within the sector, INSILICO fell 2.57%, WUXI APPTEC fell 2.02%, XTALPI fell 1.47%, GENSCRIPT BIO fell 0.92%, and WUXI XDC fell 4.15%. The company is scheduled to report interim results on August 25.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02269","symbol_name":"药明生物","start_time":0,"source_url":"","article_id":"1184004568","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1184004568","pubTimestamp":1785378544,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 30, WUXI BIO fell 3.15% in regular trading, trading at HK$38.18/share, with turnover of HK$278 million. The decline came amid broad-based weakness across the Life Sciences Tools and Services...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02269":"药明生物"},"translate_title":"走势提醒|药明生物常规交易下跌3.15%，子公司面临降价目标，生命科学板块普遍走弱","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02269":1},"content_text":"On July 30, WUXI BIO fell 3.15% in regular trading, trading at HK$38.18/share, with turnover of HK$278 million. The decline came amid broad-based weakness across the Life Sciences Tools and Services sector.On the news front, the selloff appears linked to sector-wide profit-taking following a strong recent rally, compounded by Nomura's downgrade of WUXI BIO's subsidiary WUXI XDC's target price from HK$87.73 to HK$82.6 on July 29. Nomura cited higher FX losses and elevated management expenses related to the Dong Yao Pharma acquisition, cutting its fiscal year earnings forecast by 22.3%. WUXI XDC itself declined over 4% on the day.Within the sector, INSILICO fell 2.57%, WUXI APPTEC fell 2.02%, XTALPI fell 1.47%, GENSCRIPT BIO fell 0.92%, and WUXI XDC fell 4.15%. The company is scheduled to report interim results on August 25.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}